News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
677,959 Results
Type
Article (38737)
Company Profile (248)
Press Release (638974)
Section
Business (203412)
Career Advice (1977)
Deals (35344)
Drug Delivery (78)
Drug Development (80560)
Employer Resources (167)
FDA (15995)
Job Trends (14776)
News (343498)
Policy (32402)
Tag
Academia (2528)
Africa (712)
Alliances (48944)
Alzheimer's disease (1134)
Approvals (15932)
Arizona (169)
Artificial intelligence (65)
Asia (36736)
Australia (5976)
Bankruptcy (350)
Best Places to Work (11229)
Biosimilars (62)
Biotechnology (172)
C2C Services and Suppliers (78820)
California (1648)
Canada (860)
Cancer (337)
Career advice (1647)
Cell therapy (101)
China (120)
Clinical research (62973)
Collaboration (113)
Colorado (65)
Compensation (61)
Connecticut (64)
COVID-19 (2479)
Cystic fibrosis (72)
Data (169)
Diabetes (70)
Diagnostics (5950)
Drug pricing (61)
Earnings (83623)
Employer resources (142)
Europe (78463)
Events (107528)
Executive appointments (111)
FDA (16178)
Florida (230)
Funding (108)
Gene therapy (80)
GLP-1 (500)
Government (4283)
Healthcare (18582)
Hotbed/Location (480981)
Illinois (239)
Indiana (136)
Infectious disease (2503)
Inflammatory bowel disease (86)
Interviews (305)
IPO (16173)
Job creations (3618)
Job search strategy (1412)
Kansas (93)
Layoffs (391)
Legal (7828)
Lung cancer (73)
Manufacturing (74)
Maryland (358)
Massachusetts (1358)
Medical device (13021)
Medtech (13024)
Mergers & acquisitions (18999)
Metabolic disorders (223)
Michigan (118)
Minnesota (205)
Neuroscience (1259)
New Jersey (500)
New York (518)
NextGen Class of 2024 (6479)
Non-profit (4452)
North Carolina (572)
Northern California (747)
Obesity (137)
Ohio (98)
Opinion (169)
Patents (63)
Pennsylvania (537)
People (55743)
Pharmaceutical (59)
Phase I (19504)
Phase II (27737)
Phase III (20728)
Pipeline (99)
Postmarket research (2546)
Preclinical (8297)
Press Release (64)
Rare diseases (116)
Real estate (5880)
Recruiting (63)
Regulatory (21151)
Research institute (2301)
Resumes & cover letters (345)
South America (1085)
Southern California (667)
Startups (3554)
Texas (200)
United States (7708)
Vaccines (450)
Washington State (236)
Weight loss (119)
Date
Last 7 days (578)
Last 30 days (2032)
Last 365 days (37166)
2024 (25017)
2023 (40074)
2022 (51174)
2021 (55715)
2020 (54088)
2019 (46541)
2018 (35021)
2017 (32119)
2016 (31488)
2015 (37561)
2014 (31327)
2013 (26347)
2012 (28571)
2011 (29265)
2010 (27328)
677,959 Results for "santen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen:
July 18, 2023
·
15 min read
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
Santen Pharmaceutical Co., Ltd. announced that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.
July 18, 2023
·
2 min read
Santen Announces Health Canada Approval for Cationorm® Plus to Relieve the Symptoms of Dry Eye and Ocular Allergy
Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), today announced the approval of Cationorm® Plus by Health Canada.
October 6, 2022
·
5 min read
FDA
Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.
September 26, 2022
·
7 min read
Biotech Bay
Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States
Santen’s Verkazia ® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States.
May 2, 2022
·
4 min read
Business
Visiox Pharma Licenses OMLONTI®
Visiox Pharma, Inc. today announced it has entered into a definitive agreement with Santen Pharmaceutical Co., Ltd to license OMLONTI ®.
July 19, 2023
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
3 min read
·
Voyager Therapeutics, Inc.
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.
Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).
June 20, 2024
·
4 min read
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).
June 28, 2024
·
4 min read
1 of 67,796
Next